Long non‐coding RNA PVT1: Emerging biomarker in digestive system cancer

The digestive system cancers are leading cause of cancer‐related death worldwide, and have high risks of morbidity and mortality. More and more long non‐coding RNAs (lncRNAs) have been studied to be abnormally expressed in cancers and play a key role in the process of digestive system tumour progres...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cell proliferation Ročník 50; číslo 6
Hlavní autoři: Zhou, Dan‐Dan, Liu, Xiu‐fen, Lu, Cheng‐wei, Pant, Om Prakash, Liu, Xiao‐dong
Médium: Journal Article
Jazyk:angličtina
Vydáno: England John Wiley & Sons, Inc 01.12.2017
John Wiley and Sons Inc
Témata:
Animals
Biomarkers
Cancer
Cell proliferation
Cell Proliferation - genetics
Colorectal carcinoma
Digestive system
Drug resistance
Epithelial-Mesenchymal Transition - genetics
Esophagus
Gastric cancer
Gene Expression Regulation, Neoplastic - genetics
Hepatocellular carcinoma
Humans
Medical prognosis
Mesenchyme
Metastases
Morbidity
Myc protein
Non-coding RNA
Pancreatic cancer
Pancreatic carcinoma
Plasmacytoma
Prognosis
Review
Ribonucleic acid
Risk factors
RNA
RNA, Long Noncoding - genetics
Stomach Neoplasms - genetics
Survival
Translocation
Tumors
ISSN:0960-7722, 1365-2184, 1365-2184
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:The digestive system cancers are leading cause of cancer‐related death worldwide, and have high risks of morbidity and mortality. More and more long non‐coding RNAs (lncRNAs) have been studied to be abnormally expressed in cancers and play a key role in the process of digestive system tumour progression. Plasmacytoma variant translocation 1 (PVT1) seems fairly novel. Since 1984, PVT1 was identified to be an activator of MYC in mice. Its role in human tumour initiation and progression has long been a subject of interest. The expression of PVT1 is elevated in digestive system cancers and correlates with poor prognosis. In this review, we illustrate the various functions of PVT1 during the different stages in the complex process of digestive system tumours (including oesophageal cancer, gastric cancer, colorectal cancer, hepatocellular carcinoma and pancreatic cancer). The growing evidence shows the involvement of PVT1 in both proliferation and differentiation process in addition to its involvement in epithelial to mesenchymal transition (EMT). These findings lead us to conclude that PVT1 promotes proliferation, survival, invasion, metastasis and drug resistance in digestive system cancer cells. We will also discuss PVT1's potential in diagnosis and treatment target of digestive system cancer. There was a great probability PVT1 could be a novel biomarker in screening tumours, prognosis biomarkers and future targeted therapy to improve the survival rate in cancer patients.
Bibliografie:Funding information
This work was supported by grants from The First Hospital of Jilin University Grant (grant number JDYY72016055).
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:0960-7722
1365-2184
1365-2184
DOI:10.1111/cpr.12398